A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Bevacizumab in ovarian cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
Overview
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer is a phase 1/2 interventional study registered as NCT07042802 by Nanjing Leads Biolabs Co.,Ltd, with 180 participants planned, started 2025-12-02 and due to reach its primary completion in 2027-12-25. Interventions recorded: LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Shares Nanjing Leads Biolabs, Bevacizumab.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Shares Nanjing Leads Biolabs, Bevacizumab.
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares Bevacizumab, Ovarian cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.